AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
You may also be interested in...
AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.
AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.
Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD Is The Likely Culprit
Abbott and AstraZeneca aren't providing any details about why the FDA issued a "complete response" letter for their cholesterol-lowering combo drug Certriad (rosuvastatin/fenofibric acid delayed release). But given that the fixed-dose combination pill combines two already marketed drugs - AstraZeneca's statin Crestor and Abbott's triglyceride-lowering medication TriLipix - it's likely the agency's concerns have more to do with efficacy than safety